Close Menu

NEW YORK ─ Luminex on Friday announced that it has received $11.3 million in funding from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to support the development and validation of a multiplex respiratory panel for flu A/B, respiratory syncytial virus (RSV), and SARS-CoV-2 targets on its Aries systems.

BARDA announced separately that the Luminex TaqMan-based panel will maximize benefits from two of its current assays ─ Aries SARS-CoV-2 and Aries Flu A/B & RSV ─ and offer independent results for the four targets.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.